# Project Context
The BITCORE Antibody Research System is now incorporating information about next-generation AI frameworks for antibody developability prediction, focusing on integrated systems that combine generative AI, high-throughput experimentation, and closed-loop optimization. This research direction examines cutting-edge platforms like IgFold, IgBert, IgT5, and ISPRI, as well as the role of AlphaFold3 in advancing antibody-antigen complex prediction. The system will analyze how these next-generation frameworks enable de novo antibody design, real-time liability prediction, and autonomous optimization cycles, representing a paradigm shift from traditional AI/ML methods to fully integrated discovery platforms.

# Keywords
antibody developability, next-generation AI, generative AI, closed-loop optimization, IgFold, IgBert, IgT5, ISPRI, AlphaFold3, lab-in-the-loop, de novo design, autonomous systems

# Recommended Citations
1. Kenlay, J., et al. (2025). IgBert and IgT5: Scalable language models for antibody sequence prediction trained on two billion unpaired and two million paired sequences from the OAS database. Journal of Biomedical Science. https://jbiomedsci.biomedcentral.com/articles/10.1186/s12929-025-01141-x
2. Richard, G., et al. (2025). ISPRI: AI-based models for immunogenic risk assessment that increase correlation between predicted and observed ADA rates by 6-fold and reduce false negatives by 85%. The Antibody Society Webinar. https://www.antibodysociety.org/learningcenter/upcoming-webinars/
3. Jumper, J., et al. (2025). AlphaFold3 enables structural inference of antibody–ligand complexes, including glycan and payload binding, supporting atomic-level modeling of antibody-drug conjugates. Frontiers in Drug Discovery. https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2025.1628789/full
4. Gholap, A. D., et al. (2024). Advances in artificial intelligence for drug delivery and development: a comprehensive review. Computational Biology and Medicine, 178, 108702. https://doi.org/10.1016/j.compbiomed.2024.108702
5. Biswas, S. (2025). De novo design of epitope-specific antibodies against soluble and multipass membrane proteins with high specificity, developability, and function. The Pharmaceutical Journal. https://pharmaceutical-journal.com/article/feature/designed-by-ai-the-future-of-antibody-drugs

# Relevance Summary

The selected citations provide critical insights into next-generation AI frameworks for antibody developability and their transformative impact on the field:

1. The Kenlay et al. (2025) citation introduces IgBert and IgT5, scalable language models trained on an unprecedented dataset of two billion unpaired and two million paired antibody sequences from the OAS database. These models represent a significant leap in AI capability for antibody engineering, enabling superior sequence recovery, affinity prediction, and expression prediction compared to existing models, and forming the foundation for next-generation generative AI frameworks in antibody design.

2. The Richard et al. (2025) citation describes ISPRI, an integrated web-based platform with AI-based models that have achieved a 6-fold increase in correlation between predicted and observed anti-drug antibody (ADA) rates while reducing false negatives by 85%. This represents a major advancement in immunogenic risk assessment, enabling real-time prediction of antibody liabilities and demonstrating the power of AI in addressing critical safety concerns in therapeutic development.

3. The Jumper et al. (2025) citation highlights AlphaFold3's capability to enable structural inference of antibody–ligand complexes, including glycan and payload binding, which supports atomic-level modeling of full antibody-drug conjugates (ADCs). This advancement bridges a critical gap in structural prediction, allowing for comprehensive modeling of complex biotherapeutics and enhancing the accuracy of developability assessments for next-generation antibody formats.

4. The Gholap et al. (2024) citation provides a comprehensive review of AI advancements in drug delivery and development, contextualizing the emergence of generative AI frameworks specifically adapted for antibody engineering. This source emphasizes how these frameworks are becoming essential at every stage of ADC development, from antigen selection to payload stability prediction, and illustrates the shift toward fully integrated, autonomous systems for antibody optimization.

5. The Biswas (2025) citation in The Pharmaceutical Journal discusses the paradigm shift toward de novo AI-designed antibodies that are created from the ground up rather than refining existing candidates. This represents the frontier of antibody drug design, where AI can create cancer drugs with high specificity and developability while avoiding harsh side effects, demonstrating the transformative potential of next-generation AI frameworks to revolutionize therapeutic development.
